Cheng reported that high HER2 expression enhances the radiation tolerance of patients with esophageal cancer,261 and the anti‐HER2 monoclonal antibody trastuzumab can prolong the survival of patients with HER2‐positive metastatic esophageal cancer.2 This evidence concerns the gene ERBB2 and esophageal cancer.